These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 33326338)

  • 21. Efficacy and safety of different regimens for primary open-angle glaucoma or ocular hypertension: a systematic review and network meta-analysis.
    Li F; Huang W; Zhang X
    Acta Ophthalmol; 2018 May; 96(3):e277-e284. PubMed ID: 29144028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% t.i.d. in patients with open-angle glaucoma or ocular hypertension. a 6-month, randomized, multicenter study. German Latanoprost Study Group.
    Diestelhorst M
    Graefes Arch Clin Exp Ophthalmol; 2000 May; 238(5):433-9. PubMed ID: 10901475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence.
    Zimmerman TJ; Hahn SR; Gelb L; Tan H; Kim EE
    J Ocul Pharmacol Ther; 2009 Apr; 25(2):145-52. PubMed ID: 19284321
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progression of visual field in patients with primary open-angle glaucoma - ProgF study 1.
    Aptel F; Aryal-Charles N; Giraud JM; El Chehab H; Delbarre M; Chiquet C; Romanet JP; Renard JP
    Acta Ophthalmol; 2015 Dec; 93(8):e615-20. PubMed ID: 26095771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Persistence and treatment patterns of fixed combination drugs for glaucoma: a retrospective claims database study in Japan.
    Kashiwagi K; Chono E; Koesters S; Yap PS
    BMC Ophthalmol; 2020 Jun; 20(1):223. PubMed ID: 32522181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Ocular hypotensive effect of systemic beta-blockers in patients with primary glaucoma and arterial hypertension].
    Onishchenko AL; Kolbasko AV; Zakharova AV; Onishchenko EG; Zhilina NM
    Vestn Oftalmol; 2017; 133(2):46-51. PubMed ID: 28524139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term outcomes of prostaglandin analog versus timolol maleate in ocular hypertensive or primary open-angle glaucoma patients in Europe.
    Holló G; Thelen U; Teus MA; Quaranta L; Ferkova S; Babić N; Misiuk-Hojlo M; Mikropoulos DG; Kaluzny BJ; Kozobolis V; Januleviciene I; Kóthy P; Camara C; Russo A; Krzyzanowska-Berkowska P; Cieślińska I; Stewart JA; Kristoffersen MS; Nelson LA; Stewart WC
    J Ocul Pharmacol Ther; 2011 Oct; 27(5):493-8. PubMed ID: 21790326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patients' and physicians' perceptions of the travoprost dosing aid: an open-label, multicenter study of adherence with prostaglandin analogue therapy for open-angle glaucoma or ocular hypertension.
    Flowers B; Wand M; Piltz-Seymour J; Berke SJ; Day D; Teague J; Smoot TM; Landry TA; Bergamini MV; Mallick S;
    Clin Ther; 2006 Nov; 28(11):1803-11. PubMed ID: 17213000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of the water-drinking test in medically treated primary open angle glaucoma patients.
    Salcedo H; Arciniega D; Mayorga M; Wu L
    J Fr Ophtalmol; 2018 May; 41(5):421-424. PubMed ID: 29778281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tolerability and efficacy of bimatoprost 0.01 % in patients with open-angle glaucoma or ocular hypertension evaluated in the Taiwanese clinical setting: the Asia Pacific Patterns from Early Access of Lumigan 0.01 % (APPEAL Taiwan) study.
    Chen YY; Wang TH; Liu C; Wu KY; Chiu SL; Simonyi S; Lu DW
    BMC Ophthalmol; 2016 Sep; 16(1):162. PubMed ID: 27633513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intraocular pressure response to medication in a clinical setting: the Marshfield Clinic Personalized Medicine Research Project.
    McCarty CA; Mukesh BN; Kitchner TE; Hubbard WC; Wilke RA; Burmester JK; Patchett RB
    J Glaucoma; 2008 Aug; 17(5):372-7. PubMed ID: 18703947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intraocular pressure control and persistence on treatment in glaucoma and ocular hypertension.
    Tingey D; Bernard LM; Grima DT; Miller B; Lam A
    Can J Ophthalmol; 2005 Apr; 40(2):161-9. PubMed ID: 16049529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An economic analysis of switching to latanoprost from a beta-blocker or adding brimonidine or latanoprost to a beta-blocker in open-angle glaucoma or ocular hypertension.
    Stewart WC; Leech J; Sharpe ED; Kulze J; Ellyn J; Day DG
    Am J Manag Care; 2002 Aug; 8(10 Suppl):S240-8. PubMed ID: 12188166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effects of reading, exercise and exercise combined with reading on intraocular pressure for patients sustaining primary glaucoma (open angle) or ocular hypertension, both clinically controlled with topic medication].
    Medina AM; Lima NV; Santos RC; Pereira MC; Santos PM
    Arq Bras Oftalmol; 2007; 70(1):115-9. PubMed ID: 17505730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Satisfaction and compliance of ocular hypertensive and glaucoma patients topically treated with a combination therapy].
    Bron A; Baudouin C; Denis P; Nordmann JP; Renard JP; Rouland JF; Sellem E
    J Fr Ophtalmol; 2008 Sep; 31(7):659-65. PubMed ID: 18971850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the effects of travoprost, latanoprost and bimatoprost on ocular circulation: a 6-month clinical trial.
    Koz OG; Ozsoy A; Yarangumeli A; Kose SK; Kural G
    Acta Ophthalmol Scand; 2007 Dec; 85(8):838-43. PubMed ID: 17680841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost of the medical management and prescription pattern for primary open angle glaucoma (POAG) in Ghana-a retrospective cross-sectional study from three referral facilities.
    Ocansey S; Kyei S; Diafo A; Darfor KN; Boadi-Kusi SB; Aglobitse PB
    BMC Health Serv Res; 2016 Jul; 16():282. PubMed ID: 27430262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and side effects of latanoprost monotherapy compared to adding dorzolamide to timolol in patients with glaucoma and ocular hypertension--a three-month randomised study. Spanish Latanoprost Study Group.
    García Sanchez J
    Eur J Ophthalmol; 2000; 10(3):198-204. PubMed ID: 11071026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Persistency and clinical outcomes associated with latanoprost and beta-blocker monotherapy: evidence from a European retrospective cohort study.
    Diestelhorst M; Schaefer CP; Beusterien KM; Plante KM; Fain JM; Mozaffari E; Dhawan R
    Eur J Ophthalmol; 2003 Jul; 13 Suppl 4():S21-9. PubMed ID: 12948050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Effect of Long-term Antiglaucomatous Drug Administration on Central Corneal Thickness.
    Schrems WA; Schrems-Hoesl LM; Mardin CY; Horn FK; Juenemann AG; Kruse FE; Braun JM; Laemmer R
    J Glaucoma; 2016 Mar; 25(3):274-80. PubMed ID: 25383467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.